Intelgenx Technologies Corp banner

Intelgenx Technologies Corp
TSX:IGX

Watchlist Manager
Intelgenx Technologies Corp Logo
Intelgenx Technologies Corp
TSX:IGX
Watchlist
Price: 0.24 CAD Market Closed
Market Cap: CA$41.9m

Intelgenx Technologies Corp
Other Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Intelgenx Technologies Corp
Other Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Items CAGR 3Y CAGR 5Y CAGR 10Y
Intelgenx Technologies Corp
TSX:IGX
Other Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Other Items
-$188m
CAGR 3-Years
-75%
CAGR 5-Years
N/A
CAGR 10-Years
36%
Sundial Growers Inc
NASDAQ:SNDL
Other Items
-CA$13m
CAGR 3-Years
64%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Other Items
-$50.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Other Items
-$186.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
Other Items
-CA$19.8m
CAGR 3-Years
N/A
CAGR 5-Years
10%
CAGR 10-Years
13%
No Stocks Found

Intelgenx Technologies Corp
Glance View

Market Cap
41.9m CAD
Industry
Pharmaceuticals

IntelGenx Technologies Corp. is a oral drug delivery company, which focuses on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilm technology platform. The company is headquartered in Saint-Laurent, Quebec. The company went IPO on 2008-05-23. The firm is focused on the development and manufacturing of pharmaceutical films. The firm's pharmaceutical film technologies include VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, which allows pharmaceutical products that address unmet medical needs. The firm's product pipeline offers various benefits to patients and physicians for many therapeutic conditions. Its VersaFilm research and development (R&D) services are based on a versatile drug delivery platform technology that enables the development of oral thin films exhibiting improved product performance. Its VetaFilm R&D services and veterinary oral films provide various market opportunities for improved drug delivery for companion animals. Its product portfolio includes RIZAPORT (Rizatriptan), EXORDIA (Tadalafil), Loxapine, Montelukast, Buprenorphine / Naloxone, and Dronabinol AdVersa (Dronabinol).

IGX Intrinsic Value
Not Available

See Also

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett